A Placebo Controlled Randomized, 12-Week, Dose-Ranging, Double-Blind Study Versus Placebo Using Tolterodine as a Study Calibrator, to Evaluate Efficacy and Safety of SSR240600C [SSR240600] in Women With Overactive Bladder Including Urge Urinary Incontinence.

Trial Profile

A Placebo Controlled Randomized, 12-Week, Dose-Ranging, Double-Blind Study Versus Placebo Using Tolterodine as a Study Calibrator, to Evaluate Efficacy and Safety of SSR240600C [SSR240600] in Women With Overactive Bladder Including Urge Urinary Incontinence.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 May 2016

At a glance

  • Drugs SSR 240600 (Primary) ; Tolterodine
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Acronyms BILADY
  • Sponsors Sanofi
  • Most Recent Events

    • 27 Dec 2012 New source identified and integrated (German Clinical Trials Register: DRKS00004145).
    • 16 Mar 2012 This trial is recruiting in France and discontinued in Netherlands.
    • 16 Mar 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top